Vaccine News and Research

Latest Vaccine News and Research

China SFDA awards Jiangsu Yanshen a new drug certificate and production license for its H1N1 vaccine

Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China, today announced that Jiangsu Yanshen Biological Technology Stock Co., Ltd ("Jiangsu Yanshen"), in which Simcere holds a 37.5% stake, was awarded a new drug certificate and production license from China's State Food and Drug Administration (SFDA) on September 18 for Jiangsu Yanshen's H1N1 vaccine.

22 Sep 2009

T-System revises its H1N1 point-of-care charting templates

T-System, Inc., the nation's largest provider of emergency department (ED) clinical documentation tools, today announced it has issued revised H1N1 point-of-care charting templates reflecting the most recent recommendations of the Centers for Disease Control and Prevention (CDC).

22 Sep 2009

CDC recommends seasonal influenza vaccination to counter H1N1

Public health experts, including the Centers for Disease Control and Prevention (CDC), recommend seasonal influenza vaccination as the first line of defense this year in protecting against the influenza virus.

22 Sep 2009

Antigen to block infection by genetically-diverse strains of HIV

Scientists working to develop a vaccine for the human immunodeficiency virus (HIV) report they have created the first antigen that induces protective antibodies capable of blocking infection of human cells by genetically-diverse strains of HIV. The new antigen differs from previously-tested vaccines by virtue of its chemically-activated property that enables close sharing of electrons and produces strong covalent bonding.

22 Sep 2009

U.S. HHS orders for an additional 29 million doses of MedImmune's influenza vaccine

MedImmune announced today that the U.S. Department of Health and Human Services (HHS) has placed an order for an additional 29 million doses of its live attenuated influenza vaccine (LAIV) against the 2009 H1N1 influenza virus. This brings HHS orders to date to more than 40 million vaccine doses, with a total cumulative contract value of approximately $453 million.

22 Sep 2009

Study on mice reveals that short term stress can prevent cancer

Researchers at the Stanford University School of Medicine have shown that, at least in laboratory mice, bouts of relatively short-term stress can boost the immune system and protect against one type of cancer. Furthermore, the beneficial effects of this occasional angst seem to last for weeks after the stressful situation has ended. The finding is surprising because chronic stress has the opposite effect -- taxing the immune system and increasing susceptibility to disease.

22 Sep 2009

President Obama silent on the creation of a Global Fund for Education: Global AIDS Alliance

One year ago, on September 28, 2008, then-Candidate Barack Obama used the world stage provided by the annual meeting of the Clinton Global Initiative to promise that, if elected, he would work to create a Global Fund for Education.

22 Sep 2009

GeoVax requests FDA meeting to discuss IND for its therapeutic HIV/AIDS vaccine

GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that it has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) to discuss a proposed IND for GeoVax's therapeutic vaccine as a treatment for individuals infected with HIV/AIDS.

22 Sep 2009

Results from a trial testing a 2009 H1N1 influenza vaccine in children look promising

Early results from a trial testing a 2009 H1N1 influenza vaccine in children look promising, according to the trial sponsor, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

22 Sep 2009

Importance of residual thymopoiesis in aged adults

Doctor Manuel Leal is managing the Experimental Immune Virology Laboratory (in Virgen del Rocío University Hospital and Instituto de Biomedicina de Sevilla (IBIS), where clinic and basic science researchers work) where he leads a project to establish the functional nature of the thymus gland in adults. So far, it has been proven that this gland keeps on producing lymphocytes in the old age (Ferrando-Martínez et al. AGE, in press), which is a novelty because until very recently it was considered that this organ lost its immune capacity after the puberty.

22 Sep 2009

Researcher can anticipate immune response in Alzheimer's patients

A researcher who is working on a vaccine for Alzheimer's disease (AD) has demonstrated that it is possible to test and measure specific immune responses in mice carrying human genes and to anticipate the immune response in Alzheimer's patients. This continuing research at Ben-Gurion University of the Negev could one day lead to specific Alzheimer's vaccines that reduce plaque, neuronal damage and inflammation associated with the disease.

22 Sep 2009

Boehringer Ingelheim to acquire certain assets of Wyeth Pharmaceutical after Pfizer-Wyeth merger

Boehringer Ingelheim, a global pharmaceutical group of companies, together with its U.S. animal health business Boehringer Ingelheim Vetmedica, Inc., announced today that it has entered into an agreement with Pfizer to acquire certain assets of Wyeth Pharmaceutical's Fort Dodge Animal Health business upon the closing of the global Pfizer-Wyeth merger, which is expected to occur early in the fourth quarter.

22 Sep 2009

U.N. report calls for $1.48B to help developing nations cope with H1N1

The U.N. this week will request that wealthy nations and development banks donate $1.48 billion to help developing countries fight H1N1 (swine flu), Bloomberg reports. "Most of the money is needed for vaccines and drugs … to help the least-developed nations cope with the influenza pandemic, according to a U.N. report obtained" Monday by the news service.

21 Sep 2009

Inhalable H1N1 vaccine to arrive in U.S. first week of October, CDC says

The Centers for Disease Control and Prevention on Friday announced it anticipates 3.4 million doses of inhalable H1N1 vaccines will be available by the first week of October - the initial influx of 195 million doses purchased by the U.S. government, CNN reports. The vaccine is approved for healthy people between the ages of two and 49, but not for pregnant women (9/18).

21 Sep 2009

Nanoviricides and Southern Research sign agreement to test anti-Influenza and anti-HIV drug candidates

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reported today that it has signed a “Master Service Agreement” with the Southern Research Institute (“Southern Research”), Birmingham, AL. Southern Research is a well established, prestigious institution that has performed preclinical testing services for several vaccines and antivirals.

21 Sep 2009

Geron and Corning develop synthetic surface that supports the growth and differentiation of hESCs

Corning Incorporated (NYSE: GLW) and Geron Corporation (Nasdaq: GERN) today announced the successful development of novel synthetic surface matrices demonstrated to enhance and support the scalable manufacturing and growth of human embryonic stem cells (hESCs).

21 Sep 2009

Maxygen completes joint venture transaction with Astellas Pharma

Maxygen, Inc. (Nasdaq:MAXY) today announced the consummation of the transactions contemplated by the previously announced joint venture agreement between Maxygen and Astellas Pharma Inc. Under the joint venture transaction, which closed on September 18, 2009, the parties established a newly-formed joint venture, Perseid Therapeutics LLC, to focus on the discovery, research and development of multiple protein pharmaceutical programs.

21 Sep 2009

NIAID awards DOR BioPharma a $9M grant to develop thermostable and rapidly acting vaccines

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that it has been awarded an approximate $9.4 Million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).

21 Sep 2009

No communication to workers from employers about policies in the workplace pertaining to H1N1: Study

Most workers have not had any direction from their employers about the upcoming flu season, according to a national survey released today by Mansfield Communications Inc.

21 Sep 2009

NIAID awards Antigen Discovery a Phase II STTR grant for Chlamydia vaccine development

Antigen Discovery, Inc. ("ADi", formerly ImmPORT Therapeutics, Inc.), a leading biotech company in high throughput antigen and biomarker discovery, announced today that the Company was awarded a Phase II STTR from the National Institute of Allergy and Infectious Diseases (NIAID) under the American Recovery and Reinvestment Act (ARRA) of 2009.

21 Sep 2009

Vaccine News and Research

Latest Vaccine News and Research

China SFDA awards Jiangsu Yanshen a new drug certificate and production license for its H1N1 vaccine

T-System revises its H1N1 point-of-care charting templates

CDC recommends seasonal influenza vaccination to counter H1N1

Antigen to block infection by genetically-diverse strains of HIV

U.S. HHS orders for an additional 29 million doses of MedImmune's influenza vaccine

Study on mice reveals that short term stress can prevent cancer

President Obama silent on the creation of a Global Fund for Education: Global AIDS Alliance

GeoVax requests FDA meeting to discuss IND for its therapeutic HIV/AIDS vaccine

Results from a trial testing a 2009 H1N1 influenza vaccine in children look promising

Importance of residual thymopoiesis in aged adults

Researcher can anticipate immune response in Alzheimer's patients

Boehringer Ingelheim to acquire certain assets of Wyeth Pharmaceutical after Pfizer-Wyeth merger

U.N. report calls for $1.48B to help developing nations cope with H1N1

Inhalable H1N1 vaccine to arrive in U.S. first week of October, CDC says

Nanoviricides and Southern Research sign agreement to test anti-Influenza and anti-HIV drug candidates

Geron and Corning develop synthetic surface that supports the growth and differentiation of hESCs

Maxygen completes joint venture transaction with Astellas Pharma

NIAID awards DOR BioPharma a $9M grant to develop thermostable and rapidly acting vaccines

No communication to workers from employers about policies in the workplace pertaining to H1N1: Study

NIAID awards Antigen Discovery a Phase II STTR grant for Chlamydia vaccine development

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Vaccine News and Research

Latest Vaccine News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in